Hence, SLC25A1 has been proposed to be a novel therapeutic target in cancer, which spurred the development of selective SLC25A1 inhibitors such as BTA, CTPI-1, and CTPI-2 [6]. This evidence concerns the gene SLC25A1 and cancer.